Clinical Trial Update: GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

View source ↗

Summary

Duke University's GRETeL trial evaluating tumor response to standard radiotherapy and temozolomide in glioblastoma patients has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: Duke University | Conditions: Glioblastoma, Glioma, Malignant | Status: SUSPENDED